Clinical Trials Logo

Coronary Artery Disease clinical trials

View clinical trials related to Coronary Artery Disease.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT05654935 Withdrawn - Stroke Clinical Trials

Telerobotic Ultrasound for Carotid Imaging - Feasibility Study

Start date: March 26, 2014
Phase:
Study type: Observational

In this proposal, the investigators will demonstrate the feasibility and noninferiority of telerobotic ultrasonography as compared to traditional manual acquisition in performing a limited carotid Duplex examination and in carotid plaque detection.

NCT ID: NCT05566678 Withdrawn - Clinical trials for Coronary Artery Disease

Effect of Switching From Cigarette Smoking to THS on Systemic Endothelial Function in Subjects With Established Atherosclerotic Disease

Start date: March 15, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to demonstrate improvement in flow mediated dilation (FMD), a functional endpoint associated with the progression of atherosclerosis, when switching from cigarettes to the Tobacco Heating System (THS) in subjects with peripheral arterial disease (PAD) and/or coronary artery disease (CAD). The study is planned to be conducted in the US, Europe, and Asia.

NCT ID: NCT05163327 Withdrawn - Clinical trials for Coronary Artery Disease

Oxygen-enhanced Magnetic Resonance Imaging (OE-MRI) of the Heart: A Feasibility Study

OE-MRI
Start date: January 2023
Phase:
Study type: Observational

This exploratory pilot study aims to set up cardiac oxygen enhanced magnetic resonance imaging (OE-MRI). It will involve 10 healthy volunteers and 10 patients with known coronary artery disease (CAD) having a MRI scan. If positive, this data would be used to power an appropriately sized study assessing the utility of cardiac OE-MRI in CAD and other cardiac pathologies.

NCT ID: NCT04928092 Withdrawn - Clinical trials for Coronary Artery Disease

A Zero Acute Kidney Injury Strategy for Percutaneous Coronary Intervention in Patients With ChronicKidney Disease

Zero-AKI
Start date: January 2022
Phase:
Study type: Observational

The purpose of this study is to compare the outcomes of Percutaneous Coronary Intervention (PCI) in patients with chronic kidney disease (CKD) using smaller doses of contrast dye that are validated as being at low risk of causing injury to the kidneys, with the larger doses that are traditionally used contemporary practice.

NCT ID: NCT04870073 Withdrawn - Clinical trials for Coronary Artery Disease

Retrograde Autologous Priming and Mannitol for Reducing Hemodilution in Cardiac Surgery

RAPPER-MAN
Start date: September 21, 2022
Phase: Phase 3
Study type: Interventional

Hemodilution reduces concentrations of blood constituents: concentration of hemoglobin, red blood cells (hematocrit), physiological ions and coagulation factors that can contribute to impaired hemostasis and increasing the risk of perioperative blood transfusions. This pilot study will assess the feasibility of a large RCT to evaluate 2 techniques for reducing hemodilution during cardiac surgery: 1) retrograde autologous priming and 2) intraoperative mannitol. The aim of this pilot trial is to demonstrate feasibility of a larger trial to evaluate whether retrograde autologous priming and/or mannitol are superior to conventional priming alone.

NCT ID: NCT04738344 Withdrawn - Clinical trials for Coronary Artery Disease

Very Long Versus Overlapping Stents in Long Coronary Lesions

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

This study is performed to compare the angiographic and clinical outcomes of the use of single long stent versus overlapping stents in the treatment of long coronary lesions in patients with chronic coronary syndrome.

NCT ID: NCT04619381 Withdrawn - Clinical trials for Coronary Artery Disease

Causes of Health Disparities in African Americans With Coronary Artery Disease on Clopidogrel

Start date: March 19, 2021
Phase:
Study type: Observational

African Americans with coronary artery disease who have been prescribed clopidogrel (also known as Plavix), an antiplatelet drug will be enrolled. The purpose of this study is to help identify why African Americans are at an increased risk of having a major heart attack or stroke after a common procedure to open up blocked arteries with stents. The knowledge to be gained from this study includes: 1. A better understanding of the metabolism of the antiplatelet drug, clopidogrel, and abnormal platelet function in African Americans; this understanding may provide a basis for potential future therapy 2. A better understanding of challenges to taking clopidogrel as prescribed by a doctor and opinions about a genetic test related to this medicine.

NCT ID: NCT04481490 Withdrawn - Clinical trials for Coronary Artery Disease

A Study to Objectively Measure Physical Activity and Sedentary Behavior During Cardiac Rehabilitation

Start date: January 2022
Phase:
Study type: Observational

The purpose of this study is to assess exercise patterns during home-based or center-based cardiac rehabilitation participation.

NCT ID: NCT04379947 Withdrawn - Clinical trials for Coronary Artery Disease

Preoperative Use of Fractional Flow Reserve in CABG Use and Effectiveness of FFR-based CABG in Real-life Practice

Start date: May 2020
Phase:
Study type: Observational

The use of fractional flow reserve (FFR) to guide coronary artery bypass graft (CABG) is controversial and not ubiquitously adopted across the units. There is no definitive evidence that the use of FFR improves early clinical outcomes after CABG, with the exception of a simplification of the procedure. FFR use may help in defining the indication to the use arterial grafts, but there is no evidence that preoperative FFR lead to any benefits in terms of patency when venous grafts are used. On these grounds a large multicentric all-comers observational study is planned. The aim is to achieve a real-life picture of the FFR practice in CABG across several European and non-European units. This study will inform on the effective use rate of FFR in the CABG practice and its clinical effectiveness when compared to standard angiography-based CABG.

NCT ID: NCT04361552 Withdrawn - Clinical trials for Coronary Artery Disease

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

Start date: April 7, 2020
Phase: Phase 3
Study type: Interventional

This phase III trial compares the effect of adding tocilizumab to standard of care versus standard of care alone in treating cytokine release syndrome (CRS) in patients with SARS-CoV-2 infection. CRS is a potentially serious disorder caused by the release of an excessive amount of substance that is made by cells of the immune system (cytokines) as a response to viral infection. Tocilizumab is used to decrease the body's immune response. Adding tocilizumab to standard of care may work better in treating CRS in patients with SARS-CoV-2 infection compared to standard of care alone.